June 28 (Bloomberg) -- Justin Smith, an analyst at MF Global UK Ltd., discusses the outlook for the U.S. Food and Drug Administration's Oncologic Drugs advisory panel hearing on Roche Holding AG's breast-cancer drug Avastin. The panel heard from more than 30 speakers today to open a two-day appeals hearing at the agency's headquarters in Silver Spring, Maryland.
Basel, Switzerland-based Roche is contesting the FDA's Dec. 16 decision to withdraw Avastin's conditional approval in breast cancer after the agency said follow-up studies failed to show benefits to justify potential risks. Smith speaks with Betty Liu and Shannon Pettypiece on Bloomberg Television's "In the Loop." (Source: Bloomberg) (Bloomberg)